Hologic, Inc. (HOLX) EV/EBIT Ratio: 24.28x
Is Hologic, Inc.’s EV/EBIT ratio high or low?
Hologic, Inc.'s EV/EBIT ratio of 24.28x is 33% above its 5-year average of 18.32x, around the middle of its 5-year range (7.08x–33.56x).
The EV/EBIT ratio for Hologic, Inc. (HOLX) is 24.28x as of Wednesday, June 10, 2026. It is above its 12-month average by 7.17% (22.66x).
HOLX EV/EBIT Ratio Chart
HOLX Average EV/EBIT Ratio Chart
HOLX Current vs Average EV/EBIT Ratio Chart
HOLX EV/EBIT Ratio Metrics
EV/EBIT RATIO
24.28x
EV/EBIT RATIO AVG TTM
22.66x
EV/EBIT RATIO AVG 3Y
24.05x
EV/EBIT RATIO AVG 5Y
18.32x
EV/EBIT RATIO AVG 10Y
61.10x
EV/EBIT RATIO AVG 15Y
57.23x
EV/EBIT RATIO AVG 20Y
53.86x
CURRENT VS TTM AVG
+7.17%
CURRENT VS 3Y AVG
+0.94%
CURRENT VS 5Y AVG
+32.53%
CURRENT VS 10Y AVG
-60.26%
CURRENT VS 15Y AVG
-57.58%
CURRENT VS 20Y AVG
-54.92%
HOLX Competitors' EV/EBIT Ratio
| NAME | MARKET CAP | EV/EBIT RATIO | TTM | 3Y | 5Y |
|---|---|---|---|---|---|
| Hologic, Inc. (HOLX) | $16.97B | 24.28x | 22.66x | 24.05x | 18.32x |
| Moderna, Inc. (MRNA) | $18.40B | N/A | 23.08x | 30.94x | 30.94x |
| Align Technology, Inc. (ALGN) | $12.56B | 19.62x | 19.31x | 26.46x | 31.52x |
| BioNTech SE (BNTX) | $21.81B | N/A | 4.91x | 5.85x | 5.85x |
| Mettler-Toledo International Inc. (MTD) | $22.85B | 21.94x | 26.09x | 26.29x | 29.26x |
| Baxter International Inc. (BAX) | $10.49B | N/A | 442.63x | 243.35x | 134.31x |
| Waters Corporation (WAT) | $23.83B | 54.60x | 27.55x | 26.51x | 26.24x |
| Charles River Laboratories International, Inc. (CRL) | $9.06B | 25.46x | 62.90x | 38.55x | 35.16x |
| Bio-Rad Laboratories, Inc. (BIO) | $7.89B | 36.51x | 38.03x | 32.82x | 33.28x |
| Veeva Systems Inc. (VEEV) | $26.73B | 26.56x | 45.54x | 60.66x | 66.33x |
Hologic, Inc. EV/EBIT Ratio Formula & Definition
EV/EBIT = Enterprise Value / EBIT (TTM)
Enterprise value to EBIT compares total company value to operating earnings, accounting for depreciation unlike EV/EBITDA.
Expanded definitions: Investopedia, Wikipedia, Corporate Finance Institute
Hologic, Inc. EV/EBIT Ratio FAQ
- What is the EV/EBIT ratio for Hologic, Inc. (HOLX)?
- The EV/EBIT ratio for HOLX stock is 24.28x.
- Is Hologic, Inc.'s EV/EBIT ratio high or low?
- Hologic, Inc.'s EV/EBIT ratio of 24.28x is 33% above its 5-year average of 18.32x, around the middle of its 5-year range (7.08x–33.56x).
- What is the TTM average EV/EBIT ratio for Hologic, Inc. (HOLX)?
- The TTM average EV/EBIT ratio for HOLX stock is 22.66x.
- What is the 3Y average EV/EBIT ratio for Hologic, Inc. (HOLX)?
- The 3Y average EV/EBIT ratio for HOLX stock is 24.05x.
- What is the 5Y average EV/EBIT ratio for Hologic, Inc. (HOLX)?
- The 5Y average EV/EBIT ratio for HOLX stock is 18.32x.
- What is the 10Y average EV/EBIT ratio for Hologic, Inc. (HOLX)?
- The 10Y average EV/EBIT ratio for HOLX stock is 61.10x.
- What is the 15Y average EV/EBIT ratio for Hologic, Inc. (HOLX)?
- The 15Y average EV/EBIT ratio for HOLX stock is 57.23x.
- What is the 20Y average EV/EBIT ratio for Hologic, Inc. (HOLX)?
- The 20Y average EV/EBIT ratio for HOLX stock is 53.86x.
Hologic, Inc. EV/EBIT Ratio History
| DATE | EV/EBIT RATIO |
|---|---|
| 2026-04-07 | 24.28x |
| 2026-04-06 | 24.28x |
| 2026-04-02 | 24.17x |
| 2026-04-01 | 24.15x |
| 2026-03-31 | 24.15x |
| 2026-03-30 | 24.14x |
| 2026-03-27 | 24.17x |
| 2026-03-26 | 24.18x |
| 2026-03-25 | 24.13x |
| 2026-03-24 | 24.14x |
| 2026-03-23 | 24.17x |
| 2026-03-20 | 24.09x |
| 2026-03-19 | 24.07x |
| 2026-03-18 | 24.01x |
| 2026-03-17 | 23.98x |
| 2026-03-16 | 24.01x |
| 2026-03-13 | 24.00x |
| 2026-03-12 | 24.03x |
| 2026-03-11 | 24.09x |
| 2026-03-10 | 24.13x |
| 2026-03-09 | 24.15x |
| 2026-03-06 | 24.20x |
| 2026-03-05 | 24.20x |
| 2026-03-04 | 24.17x |
| 2026-03-03 | 24.11x |
| 2026-03-02 | 24.11x |
| 2026-02-27 | 24.08x |
| 2026-02-26 | 24.04x |
| 2026-02-25 | 24.07x |
| 2026-02-24 | 24.07x |
| 2026-02-23 | 24.10x |
| 2026-02-20 | 24.10x |
| 2026-02-19 | 24.01x |
| 2026-02-18 | 24.03x |
| 2026-02-17 | 24.01x |
| 2026-02-13 | 23.98x |
| 2026-02-12 | 23.94x |
| 2026-02-11 | 23.99x |
| 2026-02-10 | 24.01x |
| 2026-02-09 | 23.97x |
| 2026-02-06 | 23.91x |
| 2026-02-05 | 23.87x |
| 2026-02-04 | 23.84x |
| 2026-02-03 | 23.85x |
| 2026-02-02 | 23.88x |
| 2026-01-30 | 23.94x |
| 2026-01-29 | 23.96x |
| 2026-01-28 | 24.66x |
| 2026-01-27 | 24.70x |
| 2026-01-26 | 24.69x |
| 2026-01-23 | 24.65x |
| 2026-01-22 | 24.67x |
| 2026-01-21 | 24.68x |
| 2026-01-20 | 24.67x |
| 2026-01-16 | 24.63x |
| 2026-01-15 | 24.64x |
| 2026-01-14 | 24.68x |
| 2026-01-13 | 24.59x |
| 2026-01-12 | 24.59x |
| 2026-01-09 | 24.59x |
| 2026-01-08 | 24.59x |
| 2026-01-07 | 24.62x |
| 2026-01-06 | 24.60x |
| 2026-01-05 | 24.55x |
| 2026-01-02 | 24.49x |
| 2025-12-31 | 24.47x |
| 2025-12-30 | 24.49x |
| 2025-12-29 | 24.48x |
| 2025-12-26 | 24.47x |
| 2025-12-24 | 24.47x |
| 2025-12-23 | 24.59x |
| 2025-12-22 | 24.60x |
| 2025-12-19 | 24.62x |
| 2025-12-18 | 24.61x |
| 2025-12-17 | 24.61x |
| 2025-12-16 | 24.64x |
| 2025-12-15 | 24.69x |
| 2025-12-12 | 24.63x |
| 2025-12-11 | 24.58x |
| 2025-12-10 | 24.58x |
| 2025-12-09 | 24.60x |
| 2025-12-08 | 24.58x |
| 2025-12-05 | 24.62x |
| 2025-12-04 | 24.59x |
| 2025-12-03 | 24.64x |
| 2025-12-02 | 24.58x |
| 2025-12-01 | 24.58x |
| 2025-11-28 | 24.62x |
| 2025-11-26 | 24.57x |
| 2025-11-25 | 24.59x |
| 2025-11-24 | 24.56x |
| 2025-11-21 | 24.43x |
| 2025-11-20 | 24.35x |
| 2025-11-19 | 24.37x |
| 2025-11-18 | 24.35x |
| 2025-11-17 | 24.74x |
| 2025-11-14 | 24.75x |
| 2025-11-13 | 24.78x |
| 2025-11-12 | 24.88x |
| 2025-11-11 | 24.89x |
| 2025-11-10 | 24.79x |
| 2025-11-07 | 24.73x |
| 2025-11-06 | 24.75x |
| 2025-11-05 | 24.77x |
| 2025-11-04 | 24.73x |
| 2025-11-03 | 24.72x |
| 2025-10-31 | 24.67x |
| 2025-10-30 | 24.68x |
| 2025-10-29 | 24.69x |
| 2025-10-28 | 24.70x |
| 2025-10-27 | 24.68x |
| 2025-10-24 | 24.69x |
| 2025-10-23 | 24.66x |
| 2025-10-22 | 24.68x |
| 2025-10-21 | 24.69x |
| 2025-10-20 | 24.02x |
| 2025-10-17 | 23.38x |
| 2025-10-16 | 22.95x |
| 2025-10-15 | 22.47x |
| 2025-10-14 | 22.12x |
| 2025-10-13 | 21.99x |
| 2025-10-10 | 22.71x |
| 2025-10-09 | 22.98x |
| 2025-10-08 | 22.89x |
| 2025-10-07 | 22.70x |
| 2025-10-06 | 22.58x |
| 2025-10-03 | 22.86x |
| 2025-10-02 | 22.76x |
| 2025-10-01 | 22.48x |
| 2025-09-30 | 22.62x |
| 2025-09-29 | 22.51x |
| 2025-09-26 | 22.53x |
| 2025-09-25 | 22.08x |
| 2025-09-24 | 22.28x |
| 2025-09-23 | 22.67x |
| 2025-09-22 | 22.56x |
| 2025-09-19 | 22.25x |
| 2025-09-18 | 22.87x |
| 2025-09-17 | 22.85x |
| 2025-09-16 | 21.30x |
| 2025-09-15 | 21.45x |
| 2025-09-12 | 21.65x |
| 2025-09-11 | 22.27x |
| 2025-09-10 | 21.99x |
| 2025-09-09 | 22.38x |
| 2025-09-08 | 22.32x |
| 2025-09-05 | 22.39x |
| 2025-09-04 | 22.27x |
| 2025-09-03 | 22.22x |
| 2025-09-02 | 22.34x |
| 2025-08-29 | 22.51x |
| 2025-08-28 | 22.35x |
| 2025-08-27 | 22.38x |
| 2025-08-26 | 22.35x |
| 2025-08-25 | 22.51x |
| 2025-08-22 | 22.87x |
| 2025-08-21 | 22.52x |
| 2025-08-20 | 23.03x |
| 2025-08-19 | 22.73x |
| 2025-08-18 | 22.55x |
| 2025-08-15 | 22.73x |
| 2025-08-14 | 22.80x |
| 2025-08-13 | 23.10x |
| 2025-08-12 | 22.77x |
| 2025-08-11 | 22.78x |
| 2025-08-08 | 22.80x |
| 2025-08-07 | 22.76x |
| 2025-08-06 | 22.43x |
| 2025-08-05 | 22.73x |
| 2025-08-04 | 22.76x |
| 2025-08-01 | 22.52x |
| 2025-07-31 | 22.41x |
| 2025-07-30 | 22.64x |
| 2025-07-29 | 22.98x |
| 2025-07-28 | 22.87x |
| 2025-07-25 | 23.13x |
| 2025-07-24 | 23.00x |
| 2025-07-23 | 22.95x |
| 2025-07-22 | 22.76x |
| 2025-07-21 | 22.22x |
| 2025-07-18 | 22.31x |
| 2025-07-17 | 22.32x |
| 2025-07-16 | 22.27x |
| 2025-07-15 | 22.08x |
| 2025-07-14 | 22.52x |
| 2025-07-11 | 22.88x |
| 2025-07-10 | 23.24x |
| 2025-07-09 | 22.92x |
| 2025-07-08 | 22.61x |
| 2025-07-07 | 22.44x |
| 2025-07-03 | 22.57x |
| 2025-07-02 | 22.74x |
| 2025-07-01 | 22.75x |
| 2025-06-30 | 22.69x |
| 2025-06-27 | 22.65x |
| 2025-06-26 | 22.68x |
| 2025-06-25 | 22.41x |
| 2025-06-24 | 22.59x |
| 2025-06-23 | 22.46x |
| 2025-06-20 | 22.47x |
| 2025-06-18 | 22.31x |
| 2025-06-17 | 22.36x |
| 2025-06-16 | 22.70x |
| 2025-06-13 | 22.56x |
| 2025-06-12 | 22.71x |
| 2025-06-11 | 22.51x |
| 2025-06-10 | 22.69x |
| 2025-06-09 | 22.50x |
| 2025-06-06 | 22.42x |
| 2025-06-05 | 22.02x |
| 2025-06-04 | 21.85x |
| 2025-06-03 | 22.01x |
| 2025-06-02 | 21.67x |
| 2025-05-30 | 21.72x |
| 2025-05-29 | 21.97x |
| 2025-05-28 | 22.22x |
| 2025-05-27 | 21.72x |
| 2025-05-23 | 19.17x |
| 2025-05-22 | 19.23x |
| 2025-05-21 | 19.34x |
| 2025-05-20 | 19.88x |
| 2025-05-19 | 19.86x |
| 2025-05-16 | 19.98x |
| 2025-05-15 | 19.64x |
| 2025-05-14 | 19.52x |
| 2025-05-13 | 20.09x |
| 2025-05-12 | 20.64x |
| 2025-05-09 | 19.97x |
| 2025-05-08 | 19.78x |
| 2025-05-07 | 19.54x |
| 2025-05-06 | 18.79x |
| 2025-05-05 | 18.67x |
| 2025-05-02 | 19.13x |
| 2025-05-01 | 14.84x |
| 2025-04-30 | 15.06x |
| 2025-04-29 | 15.10x |
| 2025-04-28 | 15.03x |
| 2025-04-25 | 15.02x |
| 2025-04-24 | 15.09x |
| 2025-04-23 | 15.05x |
| 2025-04-22 | 15.06x |
| 2025-04-21 | 14.76x |
| 2025-04-17 | 14.91x |
| 2025-04-16 | 14.65x |
| 2025-04-15 | 14.98x |
| 2025-04-14 | 15.22x |
| 2025-04-11 | 14.98x |
| 2025-04-10 | 14.81x |
| 2025-04-09 | 15.34x |
| 2025-04-08 | 15.13x |
| 2025-04-07 | 15.82x |
| 2025-04-04 | 15.72x |
| 2025-04-03 | 15.92x |
| 2025-04-02 | 15.64x |
| 2025-04-01 | 15.84x |
| 2025-03-31 | 15.94x |
| 2025-03-28 | 15.83x |
| 2025-03-27 | 16.07x |
| 2025-03-26 | 15.87x |
| 2025-03-25 | 15.70x |
Showing the most recent 260 of 4,030 data points. The chart above shows the full history.
Related Metrics
About Hologic, Inc.
Hologic, Inc. is a medical technology company focused on designing, producing, and marketing a diverse range of diagnostic tests, medical imaging systems, and surgical solutions. Its core mission is to enhance women's health through proactive detection and effective treatment, serving patients in the United States, across Europe, the Asia-Pacific region, and various other international markets. The company operates through four distinct business units: Diagnostics, Breast Health, GYN Surgical, and Skeletal Health. Within its Diagnostics segment, Hologic provides Aptima molecular diagnostic assays for identifying infectious microorganisms, alongside Aptima viral load tests for conditions like HIV, Hepatitis C, and Hepatitis B. It also offers Aptima and Panther Fusion SARS-CoV-2 assays for detecting the virus, the ThinPrep System for cytology applications, and the Rapid Fetal Fibronectin Test to help clinicians assess the likelihood of premature birth. Furthermore, the company supplies various diagnostic tests for Group B Streptococcus. The Breast Health division delivers advanced imaging and analytical solutions, including 2D and 3D digital mammography systems with accompanying reading workstations. This segment also features minimally invasive breast biopsy guidance systems and devices, products for marking and localizing breast biopsy sites, specimen radiology tools, ultrasound solutions, connectivity options, and products supporting breast-conserving surgical procedures. For GYN Surgical needs, Hologic offers the NovaSure Endometrial Ablation System, designed to manage abnormal uterine bleeding, and the MyoSure Hysteroscopic Tissue Removal System for the excision of uterine fibroids, polyps, and other pathologies. Additionally, the Fluent Fluid Management System facilitates liquid distention during diagnostic and operative hysteroscopic interventions. The Skeletal Health segment includes the Horizon DXA, a dual-energy X-ray system, and the Fluoroscan Insight FD mini C-arm, which is utilized for minimally invasive orthopedic surgical procedures. Hologic distributes its comprehensive product portfolio through a combination of its dedicated direct sales and service teams, as well as via independent distributors and sales representatives. Established in 1985, Hologic, Inc. maintains its corporate headquarters in Marlborough, Massachusetts.
- Sector
- Healthcare
- Industry
- Medical - Instruments & Supplies
- CEO
- Paul Malenchini